Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.44 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9060529 | 1.00 | KDM1A (0.53) | KDM1AMTNR1AMTNR1BSLC6A4SLC6A2 | |
| SCHEMBL9060534 | 1.00 | KDM1A (0.53) | KDM1AMTNR1AMTNR1BSLC6A4SLC6A2 | |
| SCHEMBL9060540 | 1.00 | KDM1A (0.53) | KDM1AMTNR1AMTNR1BSLC6A4SLC6A2 | |
| SCHEMBL6399776 | 0.81 | IDO1 (0.45) | MEN1KMT2AIDO1 | |
| SCHEMBL13997856 | 0.79 | HPRT1 (0.42) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL28441445 | 0.77 | KDM1A (0.51) | KDM1AMTNR1AMTNR1BSLC6A4SLC6A2 | |
| SCHEMBL6396779 | 0.77 | IDO1 (0.45) | KDM1AMEN1KMT2AIDO1 | |
| SCHEMBL6042859 | 0.77 | KDM1A (0.47) | KDM1AMTNR1AMTNR1BSLC6A4SLC6A2 | |
| SCHEMBL18092822 | 0.76 | KDM1A (0.50) | KDM1AMTNR1AMTNR1BSLC6A4SLC6A2 | |
| SCHEMBL9387582 | 0.76 | KMT2A (0.65) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113354515-A | Synthesis method of chiral trans-2-substituted cycloalkanol | 中国科学院大连化学物理研究所 | 2021-09-07 | — | — | CN | disclosed |
| US-7479574-B2 | Method of producing macrocyclic ketone, and intermediate thereof | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2009-01-20 | — | — | US | disclosed |
| US-20070287870-A1 | Method of Producing Macrocyclic Ketone, and Intermediate Thereof | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-12-13 | — | — | US | disclosed |
| EP-1845078-A1 | PROCESS FOR PRODUCING LARGE CYCLIC KETONE AND INTERMEDIATE THEREFOR | Takasago International Corporation (JP) | 2007-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287870-A1 | Method of Producing Macrocyclic Ketone, and Intermediate Thereof | MSMO1, CYP17A1, DNMT1 | KDM1A 558/4885MTNR1A 1822/4885MTNR1B 1060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.